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In!women!only! ! ! ! !
















Genital!wartsa,!13! 100%! 0%! >90%! >90%!



























CIN!2+!! 94.9!(87.7X98.4)! 100!(94.7X100)! 96.7!(80.9!X99.8)!
VIN/!VaIN!2+!! ! 100!(82.6X100)!







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































!# *# !# *# !# # #
Insurance!! USA#(15),#
France#(1)#
!# *# !# *# !# *# !# *#
Gender! Australia#(1),#
USA#(2)#












!# *# !# *# # !# #
Vaccine!
knowledge!
USA#(3)# !# # !# # # #
Adverse!
events!





!# # !# # # #
Concomitant!
healthcare!
USA#(3)# !# # # # #

































3# Journal#titles# adolescen$.jw.#or#youth$.jw.#or#school$.jw.# 43,090#
























8# Subject#heading## Exp#patient#compliance/# 55,248#
9# 7#or#8# # 701,239#







































































































































































































































































































































































































































































































































































































































































































































































































































































































































Enrolment#data## # # # #
Age#Group# # # # #
# 16L24# 79#(49.0)# 178#(38.4)# 1# pTa<0.001#
# 25L34# 70#(43.5)# 208#(44.8)# 0.64#(0.41L0.99)# #
# >35# 12#(7.5)# 78#(16.8)# 0.28#(0.13L0.57)# #
Marital#status# # # # #
# Married/#Living#as#married## 27#(16.8)# 109#(23.5)# 1# 0.221#
# Separated/#Divorced/#widowed# 94#(58.4)# 252#(54.3)# 1.54#(0.92L2.57)# #
# Single# 40#(24.8)# 103#(22.2)# 1.22#(0.66L2.25)# #
Religion## # # # #
# Christian# 121#(75.2)# 326#(70.3)# 1# 0.495#
# Muslim# 34#(21.1)# 121#(26.1)# 0.78#(0.49L1.23)# #
# Other/#No#religion## 6#(3.7)# 17#(3.6)# 1.21#(0.46L3.19)# #
Main#Employment# # # # #
# Restaurant/bar#worker/#cleaner# 85#(52.8)# 247#(53.2)# 1# 0.916#
# Local#brew#or#street#food#vendor# 40#(24.8)# 113#(24.4)# 1.05#(0.64L1.74)# #
# Manager/#owner/#office#worker# 8#(5.0)# 34#(7.3)# 0.79#(0.33L1.89)# #
# Sex#workerb# 18#(11.2)# 46#(9.9)# 1.22#(0.59L2.53)# #
# None/#Other# 10#(6.2)# 24#(5.2)# 1.26#(0.56L2.80)# #
Maximum#education#level#attained# # # # #
# None/#Incomplete#Primary## 48#(29.8)# 162#(34.9)# 1# 0.008#
# Complete#Primary## 92#(57.1)# 214#(46.1)# 1.61#(1.04L2.51)# #
# Some#Secondary/#Higher# 21#(13.0)# 88#(19.0)# 0.66#(0.36L1.23)# #
Crowding#(number#of#people#living#in#
the#participant’s#residence)##
# # # #
# 0L2#people## 95#(56.9)# 248#(50.5)# 1# pTa=#0.116#
# 3L4#people# 45#(27.0)# 129#(26.3)# 0.64#(0.41L0.99)# #
# 5+# 27#(16.2)# 114#(23.2)# 0.29#(0.14L0.59)# #
Lifetime#number#of#sexual#partnersc## # # # #
# <5## 50#(31.9)# 179#(39.5)# 1# pTa=#0.024#
# 5#–#9# 39#(24.8)# 92#(20.3)# 1.71#(1.02L2.87)# #
# >10# 24#(15.3)# 80#(17.7)# 1.49#(0.81L2.75)# #
# Do#Not#Remember# 44#(28.1)# 102#(22.5)# 2.78#(1.33L5.82)# #
Experience#of#forced#sex#in#the#last#
3#months#before#enrolmentd#
# # # #
# No# 121#(77.1)# 378#(83.1)# 1# 0.058#
# Yes## 36#(22.9)# 77#(16.9)# 1.79#(0.98L3.23)# #
Alcohol#Consumption# # # L# #
# Never# 53#(32.9)# 193#(41.6)# 1# pTa=0.00
3#
# Monthly#–#Once#a#week## 9#(5.6)# 52#(11.2)# 0.60#(0.28L1.32)# #
# 2L3#times#a#week# 47#(29.2)# 114#(24.6)# 1.75#(1.06L2.91)# #
# >4#times#per#week## 52#(32.3)# 105#(22.6)# 2.02#(1.23L3.33)# #
TimeTupdated!data!! ! ! ! !
Current#method#of#family#planninge## # # # #
# Nothing## 50#(31.1)# 143#(31.4)# 1# 0.650#
# Oral#Pill# 29#(18.0)# 84#(18.5)# 1.04#(0.58L1.86)# #
# Injection# 45#(28.0)# 100#(22.0)# 1.30#(0.77L2.17)# #
# Condom# 30#(18.6)# 103#(22.6)# 0.83#(0.48L1.43)# #
# Other#e.g.#traditional/#calendar# 7#(4.4)# 25#(5.5)# 0.93#(0.34L2.57)# #











# No## 87#(55.4)# 268#(60.1)# 1# 0.439#
# Yes# 70#(44.6)# 178#(39.9)# 1.16#(0.79L1.71)# #
Transactional#sex#in#the#last#3#
monthsg#
# # # #
# No# 85#(53.1)# 290#(63.7)# 1# 0.002#
# Yes# 75#(46.9)# 165#(36.3)# 2.18#(0.37L0.98)# #
Partners#in#the#last#3#months## # # # #
# None/#one# 94#(58.8)# 298#(65.5)# 1# pTa=0.148#
# 2L9# 39#(24.4)# 89#(19.6)# 1.50#(0.91L2.47)# #
# >10# 18#(11.3)# 54#(11.9)# 1.30#(0.58L2.93)# #
# Don’t#remember## 9#(5.6)# 14#(3.1)# 2.52#(0.90L7.00)# #
Sexually#Transmitted#Infections#–#time#updated#data#using#s0#and#sL1#results##
Chlamydia#trachomatis# # # # #
# Negative#at#all#available#time#
points#
133#(82.6)# 431#(92.9)# 1# <0.001#
# Positive#at#one#or#more#time#
points##
28#(17.4)# 33#(7.1)# 2.76#(1.57L4.87)# #
Neisseria#gonorrhoeae## # # # #
# Negative#at#all#available#time#
points#
130#(80.8)# 426#(91.8)# 1# <0.001#
# Positive#at#one#or#more#time#
points#
31#(19.3)# 38#(8.2)# 2.58#(1.51L4.41)# #
Herpes#SimplexL2#virush# # # # #
# Negative#at#all#available#time#
points#
15#(9.4)# 70#(15.2)# 1# 0.022#
# Positive#at#one#or#more#time#
points#









































#Any!HPV! # # 0.783# 0.923# 0.926#
HPV#uninfected# #78#(48.5)# 239#(51.5)# 1# 1# 1#








# # 0.867# 0.875# 0.901#















HR/LR!HPV!infection!! # # 0.667# 0.738# 0.658#
HPV#uninfected## 78#(48.5)# 239#(51.5)# 1# 1# 1#

























































































































NIMR! T! +! Total!
T! 2869# 51# 2920#
+! 41# 108# 149#










































#Any!HPV! # # 0.540# 0.590# 0.599#
HPV#uninfected# #67#(47.9)# 211#(52.1)# 1# 1# 1#








# # 0.680# 0.612# 0.625#















HR/LR!HPV!infection!! # # 0.669# 0.738# 0.658#
HPV#uninfected## 67#(47.9)# 211#(52.1)# 1# 1# 1#






































































































































































































































































































































































































































































































































3# 344# 55.04# 55.04#
6# 201# 32.16# 87.20#
9# 53# 8.48# 95.68#
12# 19# 3.04# 98.72#









6# 78# 32.91# 32.91#
9# 131# 55.27# 88.19#
12# 14# 5.91# 94.09#
15# 7# 2.95# 97.05#
18# 4# 1.69# 98.73#











































Time!point! s–2! s–1! s0! Classification1!
Group!1! ! –! –! uninfected#
# ! +! –! clearance#
# ! –! +! acquisition2#
# ! +! +! persistence#
Group!2! –! –! –! uninfected#
# +! –! –! clearance#†#
# –! +! –! clearance†#
# –! –! +! acquisition2#
# +! +! –! clearance†#
# –! +! +! persistence#
# +! –! +! persistence#†3#
# +! +! +! persistence#
Group!3! –! –! ! uninfected#
# +! –! ! clearance#
# –! +! ! acquisition#
# +! +! ! persistence#
Group!4! ! –! ! uninfected#















































































































































































































































































































































































































































































































































































































































































1# 19.7#(16.3)# 15.6#(8.77)# 0.64#(0.43L0.95)# 0.52#(0.34L0.81)#
2# 16.2#(12.7)# 12.9#(10.8)# 0.58#(0.39L0.86)# 0.53#(0.34L0.83)#
3# 17.4#(13.2)# 16.1#(10.6)# 0.71#(0.48L1.05)# 0.59#(0.38L0.91)#
4# 13.3#(11.0)# 16.4#(12.3)# 0.82#(0.55L1.23)# 0.70#(0.45L1.08)#
Campaign) 5# 13.4#(10.6)# 14.9#(12.6)# 0.65#(0.43L0.99)# 0.59#(0.38L0.93)#
PostU
campaign)
6# 15.5##(9.99)# 19#(13.3)# 0.79#(0.53L1.19)# 0.66#(0.43L1.02)#
7# 15.6#(9.84)# 18.2#(13.3)# 0.72#(0.48L1.09)# 0.67#(0.44L1.04)#
8# 19.8#(11.4)# 19#(12.5)# 0.63#(0.43L0.93)# 0.55#(0.36L0.83)#
9# 19.3#(11.1)# 16.0#(9.99)# 0.56#(0.37L0.84)# 0.50#(0.32L0.77)#




1# 3.49#(4.89)# 2.34#(2.11)# 1.09#(0.64L1.85)# 0.72#(0.39L1.32)#
2# 2.45#(2.82)# 2.10#(2.16)# 1.31#(0.76L2.26)# 0.97#(0.53L1.78)#
3# 3.55#(4.59)# 1.90#(2.30)# 0.86#(0.49L1.51)# 0.60#(0.32L1.15)#
4# 3.45#(6.07)# 2.21#(2.40)# 1.00#(0.59L1.69)# 0.70#(0.37L1.31)#
Campaign# 5# 3.07#(3.55)# 1.62#(1.72)# 0.84#(0.48L1.47)# 0.65#(0.35L1.23)#
PostU
campaign#
6# 3.83#(3.35)# 2.52#(2.64)# 1.02#(0.61L1.70)# 0.59#(0.32L1.07)#
7# 4.17#(5.66)# 1.93#(2.14)# 0.70#(0.41L1.17)# 0.45#(0.24L0.84)#
8# 4.48#(9.12)# 2.28#(2.79)# 0.77#(0.46L1.29)# 0.61#(0.33L1.11)#
9# 4.48#(7.37)# 2.17#(2.38)# 0.74#(0.44L1.24)# 0.54#(0.30L0.98)#




1# 6.97#(17.39)# 2.87#(3.26)# 1.08#(0.69L#1.70)# 0.94#(0.55L1.60)#
2# 5.73#(14.8)# 1.80#(1.61)# 0.84#(0.51L1.37)# 0.70#(0.39L1.25)#
3# 10.1#(25.4)# 2.73#(2.38)# 0.75#(0.48L1.15)# 0.68#(0.41L1.12)#
4# 7.93#(23.6)# 2.03#(1.99)# 0.72#(0.44L1.19)# 0.49#(0.27L0.89)#
Campaign# 5# 7.93#(24.0)# 2.30#(2.63)# 0.67#(0.41L1.09)# 0.64#(0.37L1.11)#
PostU
campaign#
6# 7.50#(20.6)# 3.03#(3.07)# 1.01#(0.65L1.59)# 0.83#(0.49L1.40)#
7# 7.37#(21.6)# 2.47#(2.69)# 0.80#(0.50L1.28)# 0.73#(0.42L1.25)#
8# 8.23#(22.3)# 3.40#(2.37)# 1.06#(0.69L1.62)# 0.95#(0.57L1.58)#
9# 6.83#(19.2)# 2.10#(1.83)# 0.82#(0.52L1.32)# 0.71#(0.41L1.22)#




1# 14.5#(20.5)# 8.43#(5.74)# 0.86#(0.60L1.25)# 0.40#(0.25L0.62)#
2# 11.9#(12.8)# 9.60#(6.20)# 1.15#(0.79L1.67)# 0.49#(0.31L0.78)#
3# 12.1#(14.0)# 11.2#(10.8)# 1.33#(0.91L1.94)# 0.64#(0.41L0.99)#
4# 11.3#(10.1)# 10.1#(9.34)# 1.15#(0.781.70)# 0.49#(0.31L0.77)#
Campaign# 5# 14.6#(18.7)# 11.4#(15.9)# 1.01#(0.69L1.48)# 0.48#(0.31L0.74)#
PostU
campaign#
6# 23.8#(59.#9)# 21.3#(24.3)# 1.33#(0.93L1.89)# 0.75#(0.49L1.15)#
7# 13.5#(27.3)# 12.1#(13.8)# 1.24#(0.85L1.81)# 0.62#(0.40L0.97)#
8# 15.7#(19.2)# 12.2#(13.0)# 0.94#(0.66L1.36)# 0.44#(0.29L0.69)#
9# 13.4#(13.9)# 11.6#(10.5)# 1.20#(0.82L1.76)# 0.54#(0.34L0.85)#




















1# 19.4#(20.4)# 15.3#(9.7)# 1.54#(1.05L2.25)# 0.59#(0.36L0.98)#
2# 17.8#(15.6)# 12.4#(8.70)# 0.42#(0.97L2.09)# 0.49#(0.30L0.82)#
3# 18.7#(19.1)# 12.9#(10.8)# 1.51#(1.02L2.22)# 0.50#(0.30L0.84)#
4# 20.7#(27.1)# 12.8#(11.3)# 1.03#(0.70L1.52)# 0.47#(0.29L0.78)#
Campaign# 5# 15.7#(19.4)# 13.0#(9.73)# 1.68#(1.13L2.48)# 0.75#(0.45L1.24)#
PostU
campaign#
6# 16.4#(18.2)# 12.9#(10.1)# 1.52#(1.03L2.24)# 0.57#(0.34L0.96)#
7# 17.7#(17.6)# 13.8#(10.1)# 1.67#(1.14L2.44)# 0.59#(0.36L0.98)#
8# 19.8#(14.7)# 14.7#(10.5)# 1.62#(1.11L2.37)# 0.56#(0.34L0.92)#
9# 14.9#(10.8)# 16.3#(10.2)# 2.64#(1.79L3.91)# 0.74#(0.45L1.24)#




1# 5.24#(12.2)# 1.66#(1.88)# 0.70#(0.41L1.18)# 0.58#(0.32L1.04)#
2# 4.55#(9.21)# 2.10#(1.99)# 0.99#(0.59L1.66)# 0.72#(0.39L1.33)#
3# 6.10#(19.9)# 1.48#(2.01)# 0.65#(0.37L1.14)# 0.47#(0.25L0.91)#
4# 4.86#(13.1)# 1.97#(1.70)# 0.93#(0.56L1.55)# 0.69#(0.38L1.24)#
Campaign# 5# 4.07#(7.43)# 2.97#(3.58)# 1.61#(0.97L2.66)# 1.29#(0.72L2.32)#
PostU
campaign#
6# 6.77#(18.1)# 2.52#(3.31)# 0.86#(0.52L1.42)# 0.72#(0.41L1.27)#
7# 8.03#(26.8)# 1.69#(2.14)# 0.47#(0.27L0.81)# 0.38#(0.21L0.69)#
8# 8.60#(24.9)# 2.17#(2.74)# 0.58#(0.35L0.97)# 0.53#(0.30L0.95)#
9# 7.73#(26.6)# 2.00#(1.89)# 0.66#(0.39L1.11)# 0.62#(0.35L1.10)#




1# 7.19#(18.7)# 1.77#(1.48)# 0.76#(0.47L1.23)# 0.64#(0.37L1.12)#
2# 7.90#(19.5)# 2.27#(2.12)# 0.82#(0.51L1.31)# 0.63#(0.36L1.10)#
3# 8.03#(23.9)# 2.37#(2.68)# 0.87#(0.54L1.41)# 0.67#(0.38L1.17)#
4# 8.55#(17.2)# 2.87#(3.14)# 0.75#(0.48L1.18)# 0.50#(0.29L0.85)#
Campaign# 5# 9.10#(20.6)# 2.83#(2.97)# 0.90#(0.57L1.40)# 0.73#(0.44L1.24)#
PostU
campaign#
6# 8.06#(19.8)# 2.63#(3.43)# 0.74#(0.46L1.20)# 0.55#(0.31L0.97)#
7# 6.77#(18.1)# 1.97#(2.30)# 0.82#(0.50L1.37)# 0.54#(0.29L0.99)#
8# 7.48#(16.6)# 2.10#(2.22)# 0.74#(0.46L1.18)# 0.56#(0.32L0.98)#
9# 4.65#(10.5)# 2.40#(2.18)# 1.40#(0.84L2.32)# 1.03#(0.57L1.86)#




1# 11.9#(16.6)# 12.1#(12.3)# 1.25#(0.83L1.88)# 0.77#(0.49L1.23)#
2# 13.4#(22.5)# 13.1#(13.4)# 0.97#(0.65L1.45)# 0.68#(0.44L1.06)#
3# 10.8#(14.1)# 10.8#(11.5)# 1.37#(0.89L2.09)# 0.73#(0.45L1.21)#
4# 16.5#(21.3)# 9.13#(8.63)# 0.92#(0.61L1.39)# 0.50#(0.32L0.79)#
Campaign# 5# 10.5#(10.2)# 9.07#(7.66)# 1.32#(0.87L2.00)# 0.67#(0.42L1.07)#
PostU
campaign#
6# 20.4#(22.4)# 9.07#(9.46)# 0.65#(0.43L0.98)# 0.36#(0.22L0.60)#
7# 16.4#(24.2)# 31.1#(36.4)# 1.89#(1.30L2.76)# 0.97#(0.60L1.53)#
8# 13.8#(13.9)# 11.7#(10.1)# 1.29#(0.86L1.93)# 0.80#(0.50L1.26)#
9# 19.0#(25.2)# 8.93#(6.16)# 0.73#(0.50L1.08)# 0.45#(0.29L0.71)#








































































































































































































































































































































































































































































































































































































































































































































































































































































































































TwoLthirds# of# projects/programmes# were# led# by# the# MOH,# with# lead# departments#
varying# between# cancer,# school/sexual/reproductive# health# and# EPI.# Some# early#
demonstration# projects# were# led# by# hospitals# or# nonLgovernmental# organisations#
(NGOs)#with#varying#degrees#of#national#immunisation#team#(EPI)#involvement,#a#few#
operated# without# government# input.# Some# interviewees# from# countries# without# a#
routine# school/adolescent# health# programme# reported# confusion# over# which#









with# low# EPI# involvement.# Sources# indicated# that# to# be# effective,# microplanning#


















































































































































































































































































































































































































































































































































































79.6#(2013)# Demo#1#(GAP)# School# 2009#
Demo#2#(GAP)# School# 2010L11#
National## School# 2012L#
Madagascar! Low# 77.1#(2003)# Demo#(Gavi)# School#+#health#
facility#
2013L15#
Malawi! Low# 96.9#(2009)# Demo#(Gavi)# School#+#health#
facility#
2013L15#
Mali! Low# 64.4#(2013)# Demo#(GAP)# Health#facility# 2012#
Moldova3! LowerL
middle#










Mozambique! Low# 87.4#(2013)# Demo#(Gavi)# School#+#
outreach#
2014L15#















































Sierra!Leone! Low# NA# Demo#(Gavi)# NA# 2013#
South!Africa26T29! UpperL
middle#









































































































































































































Characteristic& Uptake&(number&(%))1& Completion&(number&(%))& Final&dose&coverage2&(number&(%))&
>90%&&
&
70G89%& 50G69%& Total&& >90%& 70G89%& 50G69%& Total& >90%&& 70G89%& 50G69%& Total&
School&only& 8!(57)! 6!(43)! 0! 14! 12!(67)! 6!(33)! 0! 18! 7!(39)! 10!(56)! 1!(6)! 18!
Health&facility&
only&




15!(65)! 8!(35)! 0! 23! 15!(60)! 10!(40)! 0! 25! 14!(56)! 6!(24)! 5!(20)! 25!
All&
experiences&















Communications& !! Social!mobilisation! in! communities! should! begin! early! (at! least! one!
month!before!vaccination,!earlier!if!possible).!!




!! Members! of! government! or! WHO! representatives! should! issue!
responses!to!rumours!as!quickly!as!possible.!!
Delivery& !! In!areas!with!variable!school!attendance,!specific!mobilisation!of!out%




!! Vaccination! teams! can! include! teachers! and! CHWs! in! order! to!
decrease!the!number!of!qualified!nurses!needed!for!vaccine!delivery!
sessions.!!!




!! An! opportunity! for! girls! who! missed! doses! to! receive! the! vaccine!
should! be! supplied,! either! at! return! visits! to! schools! or! referral! to!
health! facility! or! outreach! sites,! depending! on! the! resources!
available.!!!
Sustainability&& !! More!research!should!be!conducted!on!scale%up!experiences.!
!! Further! exploration! of! sustainable! funding! options! should! be!
conducted! and! disseminated,! to! encourage! countries! to! scale%up!
demonstration!projects.!
Integration&& !! Rigorous! evaluation! of! combined! interventions! with! HPV! vaccine!
delivery!is!needed!to!assess!the!effect!on!implementation,!coverage,!
workload! and! cost.! Funding! agencies! should! systematically!
encourage!this.!
!! Gradual! integration! of! processes! into! routine! processes! should! be!
planned! and! formalised! after! the! first! round! of! vaccination! is!
completed.!
!! Opportunities! to! initiate! or! strengthen! existing! school! health!
programmes! and/or! pre%adolescent/adolescent! health! should! be!











Search  Results 
1 Papillomavirus Vaccines/ 5085 
2 hpv.ab,ti. 26945 
3 human papillomavirus.ab,ti. 23071 
4 human papilloma virus.ab,ti. 3661 
5 exp Immunization Programs/ 10517 
6 exp Vaccination/ 70018 
7 immuni$.ab,ti. 229073 
8 vaccin$.ab,ti. 225394 
9 2 or 3 or 4 33568 
10 Immunization/ 46296 
11 5 or 6 or 7 or 8 or 10 415268 
12 9 and 11 7745 
13 1 or 12 8441 
14 gambia/ 2133 
15 gambia.ab,ti. 1774 
16 14 or 15 2621 
17 limit 16 to yr="2014-Current" 150 
18 13 and 17 0 
19 senegal/ 4852 
20 senegal.ab,ti. 4103 
21 19 or 20 6035 
22 limit 21 to yr="2014-Current" 376 
23 13 and 22 2 
24 zimbabwe/ 4890 
25 zimbabwe.ab,ti. 3737 
26 24 or 25 5778 
27 limit 26 to yr="2014-Current" 299 
28 13 and 27 0 
29 chile/ 10403 
30 chile.ab,ti. 8360 
31 29 or 30 12887 
32 limit 31 to yr="2014-Current" 990 
33 13 and 32 6 
34 burkina faso/ 2398 
35 "burkina faso".ab,ti. 2409 
36 34 or 35 2980 
37 limit 36 to yr="2014-Current" 316 
38 13 and 37 0 
39 "cote d'ivoire".ab,ti. 1431 
40 cote d'ivoire/ 2595 
41 39 or 40 2969 




43 13 and 42 1 
44 ethiopia/ 7873 
45 ethiopia.ab,ti. 6694 
46 44 or 45 8911 
47 limit 46 to yr="2014-Current" 1268 
48 13 and 47 1 
49 "solomon islands".ab,ti. 508 
50 solomon islands/ 892 
51 49 or 50 1072 
52 limit 51 to yr="2014-Current" 62 
53 13 and 52 0 
54 togo/ 870 
55 togo.ab,ti. 942 
56 54 or 55 1134 
57 limit 56 to yr="2014-Current" 89 
58 13 and 57 0 
59 bhutan/ 240 
60 bhutan.ab,ti. 288 
61 59 or 60 361 
62 limit 61 to yr="2009 -Current" 188 
63 13 and 62 5 
64 bolivia/ 2013 
65 bolivia.ab,ti. 2108 
66 64 or 65 2792 
67 limit 66 to yr="2009 -Current" 939 
68 13 and 67 2 
69 botswana/ 1275 
70 botswana.ab,ti. 1364 
71 69 or 70 1648 
72 limit 71 to yr="2013 -Current" 283 
73 13 and 72 3 
74 brazil/ 62883 
75 (brazil or brasil).ab,ti. 48616 
76 74 or 75 75353 
77 limit 76 to yr="2010 -Current" 29830 
78 13 and 77 55 
79 cambodia/ 2388 
80 (cambodia or cambodge).ab,ti. 2169 
81 79 or 80 3029 
82 limit 81 to yr="2009 -Current" 1277 
83 13 and 82 5 
84 (cameroon or cameroun).ab,ti. 4286 
85 cameroon/ 4051 
86 84 or 85 5216 




88 13 and 87 7 
89 georgia/ 9405 
90 (georgia or Sakartvelo).ab,ti. 6753 
91 89 or 90 12915 
92 limit 91 to yr="2010 -Current" 2609 
93 13 and 92 18 
94 ghana/ 5275 
95 ghana.ab,ti. 5071 
96 94 or 95 6357 
97 limit 96 to yr="2013 -Current" 1228 
98 13 and 97 1 
99 guyana/ 562 
100 guyana.ab,ti. 623 
101 99 or 100 897 
102 limit 101 to yr="2012 -Current" 126 
103 13 and 102 0 
104 haiti/ 2504 
105 haiti.ab,ti. 1958 
106 104 or 105 2948 
107 limit 106 to yr="2009 -Current" 1325 
108 13 and 107 9 
109 honduras/ 907 
110 honduras.ab,ti. 1125 
111 109 or 110 1361 
112 limit 111 to yr="2011 -Current" 265 
113 13 and 112 7 
114 india/ 82017 
115 india.ab,ti. 53099 
116 114 or 115 96520 
117 limit 116 to yr="2009 -Current" 32162 
118 13 and 117 100 
119 kenya/ 12121 
120 kenya.ab,ti. 11071 
121 119 or 120 14645 
122 limit 121 to yr="2011 -Current" 3798 
123 13 and 122 13 
124 kiribati/ 1003 
125 kiribati.ab,ti. 110 
126 124 or 125 1059 
127 limit 126 to yr="2011 -Current" 163 
128 13 and 127 0 
129 (laos or lao).ab,ti. 2008 
130 laos/ 1391 
131 129 or 130 2431 




133 13 and 132 0 
134 lesotho/ 311 
135 lesotho.ab,ti. 422 
136 134 or 135 481 
137 limit 136 to yr="2009 -Current" 157 
138 13 and 137 1 
139 madagascar/ 2581 
140 madagascar.ab,ti. 3029 
141 139 or 140 3543 
142 limit 141 to yr="2013 -Current" 549 
143 13 and 142 0 
144 malawi/ 3555 
145 malawi.ab,ti. 3743 
146 144 or 145 4441 
147 limit 146 to yr="2013 -Current" 934 
148 147 and 13 3 
149 mali/ 1862 
150 mali.ab,ti. 2281 
151 149 or 150 2754 
152 limit 151 to yr="2012 -Current" 569 
153 152 and 13 5 
154 (moldova or moldavia).ab,ti. 516 
155 moldova/ 604 
156 154 or 155 882 
157 limit 156 to yr="2013 -Current" 98 
158 157 and 13 2 
159 mongolia/ 1306 
160 mongolia.ab,ti. 2126 
161 159 or 160 2647 
162 limit 161 to yr="2012 -Current" 747 
163 162 and 13 1 
164 morocco/ 4302 
165 morocco.ab,ti. 3413 
166 164 or 165 5304 
167 13 and 166 6 
168 mozambique/ 1622 
169 mozambique.ab,ti. 1974 
170 168 or 169 2323 
171 limit 170 to yr="2014 -Current" 302 
172 171 and 13 0 
173 nepal/ 5554 
174 nepal.ab,ti. 5146 
175 173 or 174 6611 
176 limit 175 to yr="2008 -Current" 3107 




178 niger/ 947 
179 niger.ab,ti. 8535 
180 178 or 179 8706 
181 limit 180 to yr="2014 -Current" 692 
182 181 and 13 0 
183 papua new guinea.ab,ti. 3512 
184 papua new guinea/ 2964 
185 183 or 184 4294 
186 limit 185 to yr="2012 -Current" 570 
187 186 and 13 1 
188 peru/ 6144 
189 peru.ab,ti. 6012 
190 188 or 189 8298 
191 limit 190 to yr="2007 -Current" 3606 
192 191 and 13 26 
193 (philippines or pilipinas or filipinas).ab,ti. 5438 
194 philippines/ 6935 
195 193 or 194 8853 
196 limit 195 to yr="2010 -Current" 1830 
197 196 and 13 4 
198 rwanda/ 1649 
199 rwanda.ab,ti. 1532 
200 198 or 199 2072 
201 limit 200 to yr="2011 -Current" 617 
202 201 and 13 8 
203 sierra leone.ab,ti. 1053 
204 sierra leone/ 948 
205 203 or 204 1290 
206 limit 205 to yr="2013 -Current" 377 
207 206 and 13 0 
208 south africa.ab,ti. 19388 
209 south africa/ 33165 
210 208 or 209 37735 
211 limit 210 to yr="2011 -Current" 8784 
212 211 and 13 36 
213 tanzania/ 8464 
214 tanzania.ab,ti. 7676 
215 213 or 214 9927 
216 limit 215 to yr="2010 -Current" 3322 
217 216 and 13 17 
218 thailand/ 21183 
219 thailand.ab,ti. 17744 
220 218 or 219 26226 
221 limit 220 to yr="2010 -Current" 7834 




223 uganda/ 8601 
224 uganda.ab,ti. 8087 
225 223 or 224 10265 
226 limit 225 to yr="2008 -Current" 4692 
227 226 and 13 32 
228 uzbekistan/ 1804 
229 uzbekistan.ab,ti. 856 
230 228 or 229 1999 
231 limit 230 to yr="2009 -Current" 242 
232 231 and 13 2 
233 vietnam/ 9403 
234 vietnam.ab,ti. 8707 
235 233 or 234 12413 
236 limit 235 to yr="2008 -Current" 4654 
237 236 and 13 27 
238 zambia/ 3347 
239 zambia.ab,ti. 3148 
240 238 or 239 4135 
241 limit 240 to yr="2013 -Current" 640 
242 241 and 13 3 
243 18 or 23 or 28 or 33 or 38 or 43 or 48 or 53 or 58 
or 63 or 68 or 73 or 78 or 83 or 88 or 93 or 98 or 
103 or 108 or 113 or 118 or 123 or 128 or 133 or 
138 or 143 or 148 or 153 or 158 or 163 or 167 or 
172 or 177 or 182 or 187 or 192 or 197 or 202 or 
207 or 212 or 217 or 222 or 227 or 232 or 237 or 
242 
398 
244 developing countries/ 65420 
245 limit 244 to yr="2007 -Current" 17905 
246 245 and 13 142 
247 GAVI.ab,ti. 238 
248 limit 247 to yr="2007 -Current" 213 
249 248 and 13 31 
250 (Low-income countries or LIC).ab,ti. 3274 
251 limit 250 to yr="2007 -Current" 2510 
252 251 and 13 19 
253 (Low-middle income countries or LMIC).ab,ti. 456 
254 limit 253 to yr="2007 -Current" 445 
255 254 and 13 2 







































































































































































































































































































































































































1& Angola& Donation! NA! NA!
2& Bangladesh& Gavi! 2015%16! Cervarix®!
3& Benin& Gavi! 2015%16! Cervarix®!
4& Burundi& Gavi! Postponed! Cervarix®!
5& Liberia& Gavi! Postponed! Gardasil®!
















































The introduction of human papillomavirus 
(HPV) vaccine has the potential to save the 
lives of millions of women and girls worldwide. 
Based on a review conducted by the London 
School of Hygiene & Tropical Medicine and 
PATH, this brief highlights findings, key lessons 
and recommendations relevant to the theme 
of HPV vaccination achievements.
Findings and key lessons  
VACCINE COVERAGE
Forty-nine of a total of 72 HPV vaccine delivery experiences 
had data on final dose coverage. Coverage was defined as 
the total number of girls receiving all HPV doses out of the 
total estimated eligible population. In general, coverage 
was good, with 84% of delivery experiences reporting 70% 
coverage or higher. No project/programme reported less 
than 50% coverage. Of those reporting coverage, 47 used a 
three-dose schedule and 2 used a two-dose schedule (revised 
recommendations from the World Health Organization for the 
two-dose schedule were only released in late 2014).
Only five projects/programmes that vaccinated solely in health 
facilities reported coverage; in general, these had lower coverage 
than those that included schools. One national programme that 
employed different strategies over a five-year period found that 
school-based delivery resulted in 90% coverage, compared to 65% 
coverage using health-facility-based delivery.
Key lesson: Achieving high HPV vaccine coverage is 
feasible in low- and middle-income countries. 
Key lesson: Vaccine delivery strategies that included a 
school-based component resulted in higher coverage, 
compared with those that only used health facilities for 
vaccinations.
UPTAKE AND DROPOUT  
Vaccine uptake (first-dose coverage) reported by 28 delivery 
Achievements












experiences ranged from 74% to greater than 100%. 
Completion rates (proportion of initiators receiving all doses) 
were reported by 48 delivery experiences and ranged from 
73% to 99%. Sixty per cent of reported delivery experiences 
achieved a vaccination completion rate of 90% or more. 
Several factors helped with tracking doses, including 
vaccination registers (electronic or manual), immunisation 
cards, school staff involvement and reminders through health 
workers, churches and community forums.
Key lesson: Vaccination registers, immunisation cards 
and utilisation of community members facilitated 
tracking girls to ensure completion of all vaccine doses.
FACTORS ASSOCIATED WITH HIGH COVERAGE 
Data from 49 delivery experiences showed that factors correlated 
with high coverage (≥70%) included using schools as a location 
for vaccinations, leadership by the Expanded Programme on 
Immunization, planning and implementing in collaboration with 
education ministries and departments at national and subnational 
levels, and including vaccination opportunities for out-of-school 
and absentee girls. Other factors included comprehensive social 
mobilisation that deployed ‘credible influencers’, such as health 
workers and teachers, and vaccination registers and cards. 
Vaccination by grade was reported to be logistically easier to 
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We" are" conducting" research" on" the" impact" of" the" Human" papillomavirus" (HPV)" vaccination"





This" research" is" being" conducted" by" the" National" Institute" for"Medical" Research" (NIMR)"Mwanza"
centre"and"the"Mwanza" Intervention"Trials"Unit" (MITU)" in"collaboration"with"the"London"School"of"






























All" information" collected" in" this" study"will" be" kept" securely" and" confidential" in" a" locked" location.""
Your" name" and" details" will" not" be" recorded" on" the" notes" or," if" you" consent" to" recording" of" the"
interview,"in"the"recording."Analysis"will"only"be"done"using"the"study"number"and"your"identity"will"
remain" private" and" confidential." Reports" about" the" study" and" results" will" be" presented" to" the"
organizations"that"are"working"together" for" this"study" including" local"government,"and"at"scientific"


























•! Ms$Kate$Gallagher,"Mwanza" Intervention"Trials"Unit,"National" Institute" for"Medical"Research,"













I" agree" to" the"use"of"direct"quotes" from"my" interview" in"published" results"as" long"as" they"are"not"




" " " " " " " " " " " " " "____" " " " "
Participant"name"(print)" " " " Participant"signature" " Date"
" "
" "
" " " " " " " " " " " " " " " " " "










































e.g**Deworming*in*schools* 1*nurse*assistant* 1st*July* 1*day* *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *








e.g.*HPV*vaccine*training* * ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *
! ! ! ! *





















1! Health!Facility!Name! ! facility*










































Nurse!Assistant! ! ! ! hfnafte,*
hfnapte*
















































11! Code!of!data!collector! |__|__|__|! *
intcode*








' ! ! ! '
! ! ! ! ! ! ! !Study:'HWI'Study''' Facility!__________________________|__|__|__|! District!__________________________|__|__|!
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We! are! conducting! research! on! the! lessons! learnt! and! best! practices! from! HPV! vaccine!




The! research! is!being!conducted!by! the!London!School!of!Hygiene!and!Tropical!Medicine!
(LSHTM)!and!the!Programme!for!Appropriate!Technologies!in!Health!(PATH).!!
%
Participation%
!
We!request!your!participation!in!this!interview!because!we!believe!you!may!be!able!to!
contribute!to!our!understanding!about!past!experiences!with!HPV!vaccine!demonstration!
projects.!
Taking!part!in!the!study!is!entirely!voluntary!and!withdrawal!is!possible!at!any!time!without!
any!penalty!to!you!and!without!having!to!give!a!reason.!!
If!you!agree!to!take!part!in!this!research,!we!would!like!to!ask!you!some!questions!for!
approximately!60!minutes.!!
Risks%and%benefits%
The!research!will!in!no!way!inconvenience!you!apart!from!the!time!it!will!take!you!to!
participate!in!this!interview.!The!information!that!we!gather!from!you!and!others!interviewed!
will!assist!us!in!understanding!the!lessons!learned!from!HPV!vaccine!demonstration!
projects.!We!will!write!reports!and!other!outputs!based!on!this!information,!which!may!inform!
future!positive!developments!in!this!area.!
Confidentiality%
! !
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We!will!maintain!strict!confidentiality!throughout!this!study.!Your!name!will!not!be!linked!to!
any!quotes!or!other!results!of!this!study!or!included!in!any!reports,!even!anonymously.!
Notes!taken!during!the!interview!will!be!stored!securely^!computer!files!will!have!access!
codes!and!will!only!be!shared!among!study!team!members.!
We!appreciate!your!participation!in!this!study.!!We!thank!you!for!your!time!and!effort.!!If!you!
have!any!questions!or!concerns!about!the!study,!please!do!not!hesitate!to!contact!Dr!
Deborah!WatsonTJones,!LSHTM!&!Mwanza!Intervention!Trials!Unit,!Tanzania.!
Email:Deborah.watsonTjones@lshtm.ac.uk!!!
The!London!School!of!Hygiene!and!Tropical!Medicine!Ethical!Committee!approved!this!
study!on:!……………………………..%
%
INFORMED%CONSENT%
%
INTERVIEWS%IN%COUNTRIES%WITH%HPV%VACCINE%EXPERIENCE%
%
Research%participant%consent%form!
Principal!Investigator:!
Dr!Deborah!WatsonTJones!
London!School!of!Hygiene!&!Tropical!Medicine!
Faculty!of!Infectious!Disease!Epidemiology!
Keppel!Street!
London!!
Email:!Deborah.watsonTjones@lshtm.ac.uk!!!
Phone:!+447447300967/!+251911028612/!+255754056066!
!
!!
The!purpose!of!this!form!is!to!allow!the!use!of!your!interview!for!research!purposes!(in!
publications!or!presentations).!Please!fill!in!the!form!according!to!your!wishes.!!
!
!
Name:!!
!
!
Signature:!
!
!
Date:!
!
!
Please%tick%one%only:%
!
! !
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!
I!permit!the!use!of!anonymous!quotes!from!the!interview!
!
!
I!do!not!want!quotes!from!my!interview!to!be!used!directly!in!!
publications/!presentations.!Information!I!provide!should!only!be!!
used!aggregated!with!other!information!!!
! !
! !
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Annex%7:%Interview%topic%guides%(Objective%4)%
Lessons%learnt%from%HPV%vaccine%demonstration%projects%%
Extension%&%supplement%data%collection:%Key%Informant%Interview%Topic%Guide%for%
countries%with%HPV%vaccine%experience%
The!interview!will!involve!structured!and!open!questions!on!a!selection!of!the!following!topics!
dependent!on!what!information!is!obtained!from!the!published!and!grey!literature!review!or!
previous!interviews.!
%
%
!
1.! Decision!making:!!
•! How!was!the!decision!made!to!conduct!the!HPV!vaccine!demonstration!project?!!
!
2.! Planning:!
•! Who!was!involved!in!the!planning!(EPI/education?)?!Was!there!a!committee?!Where!
there!any!challenges!during!planning?!!
!
3.% Delivery%strategy:%
•! What%was%the%delivery%strategy%(target%population%&%venue)%for%HPV%vaccine%
delivery?%(probe%if%a%HF%only%strategy%=%how%it%worked%etc.)%
•! Did%this%change%during%the%project/programme?%(Why?%What%was%the%result?)%%
•! Are%there%plans%to%change%the%delivery%strategy%in%the%future%(if%the%
project/programme%is%on=going%or%hypothetically%would%they%use%the%same%
delivery%strategy%in%the%future)?%
•! Did%you%use%a%2=dose%or%a%3=dose%schedule?%(If%they%have%experience%in%both%–%
how%was%the%experience%delivering%2%doses%different%(ease/cost..)?)%%
•! Timing%of%vaccination%–%was%HPV%vaccination%performed%on%specific%days?%If%it%
was%provided%on%specific%days%=%How%many%days?%i.e.%was%it%campaign=like?%%
•! How%were%girls%who%were%absent%on%the%day%of%vaccination%accessed%(were%
there%‘mop=up’%activities?)?%%
•! Was%there%a%specific%delivery%strategy%for%out=of=school%girls/%identified%hard=to=
reach%girls%(what%was%it)?%
•! How%did%delivery%of%HPV%vaccine%involve%the%EPI%programme?%Challenges?%
•! If%schools%delivery%was%used%what%was%the%role%of%teachers%and%educational%
staff%in%the%delivery%(organising,%consent%taking,%follow=up%of%absentees,%
completing%reporting%forms?)?%
•! Was%HPV%vaccine%delivered%with%any%other%services%(e.g.%other%vaccines/health%
education/%child%health%interventions…)?%Lessons%learnt%from%this?%
•! Is%there%any%kind%of%other%routine%outreach%to%schools/%the%9=13%yr%old%age%
group%e.g.%Td%outreach?%What%are%the%benefits/difficulties%in%joining%HPV%
vaccine%delivery%with%this%programme?%
!
4.% Vaccine%management:%
•! Prior%to%vaccine%delivery,%how%was%the%amount%of%vaccine%required,%calculated?%
for%both%in=school%and%out=of%school%girls?%Did%this%estimate%prove%accurate?%%
•! How%was%vaccine%supplied%to%the%delivery%sites?%How%did%the%supply%chain%
differ%from%that%used%for%other%EPI%vaccines?%
•! Were%there%sufficient%supplies%of%vaccine%and%consumables%at%each%venue?%
! !
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•! How%was%the%waste%generated%by%vaccination%managed%and%disposed?%How%did%
this%differ%from%the%management%of%EPI%vaccines?%
5.! Cold!Chain:!!
•! Was!an!assessment!of!cold!chain!capacity!completed!before!implementation?!Was!
the!same!EPI!cold!chain!facilities!used!for!HPV!vaccine?!
•! Were!changes!needed!and!made!to!the!cold!chain!facilities!for!HPV!(before,!during!
or!after!HPV!vaccine!delivery)?!
!
6.! Quality/!Safety!of!care:!
•! How!were!AE/SAE!reported?!Were!there!any!AEs/SAEs?!How!were!these!dealt!
with?!
•! If!the!vaccine!was!delivered!outside!of!the!health!facility,!were!emergency!kits!
present?!Did!you!have!any!problems!with!safe!injection!procedures?!!
•! How!were!safety!processes!for!HPV!vaccine!(AE/SAE!reporting!and!safe!injection!
procedures!and!training)!different!from!what!is!done!in!the!EPI!program?!!
!
7.% Social%mobilization:%
•! Was%social%mobilization%conducted%before%HPV%vaccine%delivery?%%
•! What%were%the%key%messages%and%communication%materials%used?%
•! How%the%messages%were%delivered%(radio/%drama/%newspaper?)?%
•! Who%delivered%the%key%messages%about%HPV%vaccine%(was%it%a%MOH%
spokesperson/%community%leaders/%religious%leaders?)%%
•! Who%was%the%target%audience?%
•! When/%how%often%was%social%mobilisation%done%and%how%far%in%advance%of%
vaccination%with%each%dose?%
•! Were%vaccine%recipients%given%incentives%to%attend%the%vaccination%venue?%%
•! Were%messages%delivered%during%social%mobilization%integrated%with%
educational%messages%about%other%health%interventions/%other%vaccines%e.g.%EPI%
vaccines?%%
!
8.% The%consent%process:%
•! How%did%parents%give%permission%to%vaccinate?%Opt=in%or%opt=out?%%
•! How%were%parents%informed%about%vaccination%activities%for%opt=out%consent/%
how%were%parents%accessed%for%opt=in%consent?%Challenges?%
•! Was%the%process%the%same%as%for%other%routine%vaccinations%e.g.%infant%
vaccinations%or%TT%boosters%in%older%children?%%
!
9.% Coverage/%acceptability%of%HPV%vaccine:%%
•! Do%you%have%information%on%acceptability%of%vaccination/%refusals?%How%were%
issues%overcome?%What%did%parents%say%were%factors%that%made%them%get%their%
daughters%vaccinated/%prevented%them%getting%their%daughters%vaccinated?%%
What%were%the%reasons%for%non=vaccination?%%What%were%the%reasons%for%not%
completing%the%3=dose%series?%
•! Coverage%of%dose%1,%2%for%each%year%of%implementation?%In%school%girls%and%out%
of%school%girls?%How%were%these%calculated%–%what%was%the%denominator%used?%
•! What%aspects%of%the%project/programme%do%you%think%influenced%coverage?%
!
10.!Availability!of!health!care!staff:!!
•! How!many!staff!were!used!to!deliver!the!vaccine!at!each!vaccination!session?!Did!
this!differ!between!sessions!at!the!health!centre/!school/!other!outreach!site?!
•! Were!staff!the!same!staff!as!those!used!to!deliver!EPI!vaccines?!!!
•! How!many!individuals/schools/!communities!would!one!HW/!1!team!cover?!
! !
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•! How!long!did!vaccination!activities!take?!Did!the!vaccine!activities!affect!normal!
work?!
•! Is!there!any!evidence!of!the!extent!to!which!routine!health!care!activities!including!
routine!EPI!were!disrupted!during!HPV!vaccine!activities?!!
!
11.!Training!of!staff:!!
•! Who!participated!in!training!(District!representatives/!Number!of!HWs/!teachers/!
community!members?)?!Did!they!train!others?!Who!conducted!the!training?!
•! Did!training!reach!the!numbers!expected/!was!more!training!necessary?!
•! When!was!it!(how!long!before!vaccination)?!
•! How!long!was!it?!Is!it!now!routine!training!or!was!it!a!oneToff?!
•! Was!it!integrated!with!training!for!routine!EPI!program?!
!
12.%Remuneration%of%staff:%
•! Were%per%diems%used%to%pay%staff%for%vaccine%delivery/%to%attend%training/%to%
conduct%social%mobilization%activities?%
•! Were%incentives%to%staff%used/%helpful/%necessary%for%quality%of%care?%
•! Are%processes%for%remuneration%similar%to%EPI%vaccines?%Were%per%diems%the%
same%amount%as%given%for%routine%EPI%vaccine%delivery?%
!
13.!Performance!and!supervision!of!staff:!
•! What!support!and!supervision!of!staff!was!conducted!during!HPV!vaccine!
implementation?!
•! Was!supervision!integrated!with!other!EPI/!health!facility!supervision?!
•! Did!the!level!of!supervision!differ!from!routine!EPI!vaccine!delivery?!Why?!
!
14.!Monitoring!&!Evaluation!–!Reporting!systems!
•! How!was!data!collected!at!the!site!of!delivery!on!the!number!of!girls!vaccinated/!the!
number!who!received!dose!2!after!dose!1?!!
•! Was!the!quality!of!data!collection!assessed!or!supervised?!!
•! Were!data!collection!forms!and!subsequent!data!management!processes!integrated!
with!the!national!HMIS!/!the!routine!EPI!reporting!systems?!!
!
15.%Financial%support%for%HPV%vaccine%and%sustainability:%
•! Who%financed%the%vaccine?%
•! Who%financed%the%delivery%costs?%
•! What%are%plans%for%financing%the%HPV%programme%in%the%future?%
•! Has%a%costing%study%been%undertaken%of%the%demonstration%project/%national%
programme?%Details?%
!
16.%Scale=up%and%Value:%If%the%country%performed%a%demo/%pilot%programmei%has%there%
been%scale=up%after%the%demo%to%more%regions%or%national%roll=out?%%
If%yes:%%
•! How%was%the%decision%made%to%scale=up%from%pilot/%demo%to%a%national%
programme?%%
•! Did%the%experience/results%from%the%pilot/demo%influence%the%decision%to%scale%
up/%delivery%strategy%chosen?%%
•! Do%you%think%you%could%have%gone%straight%to%national%roll%out%if%the%funding%
was%available?%
•! How%could%the%demo(s)%have%been%more%helpful/useful?%If%you%did%it%again%
would%you%have%designed%the%demo%differently%to%make%sure%it%was%useful%when%
planning%national%programme?%%
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•! What%are%the%plans%for%HPV%vaccine%in%the%future?%Continued%natl%programme?%
(Sustainability?)%
If%no:%%
•! What%are%the%plans%for%HPV%vaccine%delivery%in%the%future?%Another%demo?%
National?%%
•! How%would%HPV%vaccine%be%delivered%in%the%future?%/%how%would%the%
programme%be%coordinated?%(Sustainability)?%
•! Will%the%demo%experience%help%in%planning%a%national%programme?%%
•! Do%you%think%you%could%have%gone%straight%to%national%roll%out%if%the%funding%
was%available?%
•! How%could%the%demo(s)%have%been%more%helpful/useful?%If%you%did%it%again%
would%you%design%the%demo%differently%to%make%sure%it%is%useful%when%planning%
a%national%programme?%%
!
!
! !
! !
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Lessons%learnt%from%HPV%vaccine%demonstration%projects%
Key%Informant%Interview%Topic%Guide:%Countries%who%have%not%yet%implemented%HPV%
vaccine%demonstration%projects.%
The!interview!will!involve!structured!and!open!questions!around!factors!influencing!the!
decision!to!implement/!notTimplement!HPV!vaccination:!
•! The!interviewee’s!role!and!experience!in!the!immunization!services!in!general!and!in!
decisions!related!to!the!HPV!vaccination!programme!specifically.!!
Factors!influencing!the!decision!on!HPV!vaccine!introduction!
•! Do!you!feel!cervical!cancer!rates!are!a!health!priority!for!the!country?!!
•! How!can!cervical!cancer!be!prevented?!Are!you!aware!that!there!is!a!vaccine!against!
HPV?!
•! Are!you!aware!that!HPV!vaccine!is!available!through!GAVI!funding!(free!for!a!
demonstration!project,!subsidised!for!a!national!programme)?!!!
•! In!your!view,!what!are!the!key!reasons!why!HPV!vaccine!has!not!yet!been!
introduced/!an!application!to!GAVI!for!funding!for!introduction!of!HPV!vaccine!has!not!
been!made?!!
•! Are!there!other!interventions!which!are/will!be!prioritised!before!HPV!vaccine?!For!
what!reasons?!
•! Have!there!been!discussions!in!the!MOH!on!the!opportunity!to!introduce!HPV!
vaccine?!Who!has!been!involved!in!these!discussions!(roles/!titles!(not!names))?!
What!have!been!the!outcomes!of!these!discussions/!what!are!the!key!points!raised!
by!different!stakeholders?!
•! If!so,!what!information!was!needed!in!those!discussions!or!what!would!be!needed!
now!if!discussions!were!to!take!place!about!introducing!HPV!vaccine!in!a!pilot/!
national!programme?!!
•! Does!the!country!have!experience!of!GAVI!Alliance!funding?!What!was!the!
experience!(were!there!particular!benefits/!drawbacks!that!you!know!of?)!
!
Decision!processes!!
•! How!are!decisions!made!on!whether!to!introduce!new!vaccines?!(Probes:!are!there!
committees!e.g.!an!immunization!advisory!committee?!Who!is!involved?!Are!
stakeholders!from!outside!the!MOH!involved?)!!
•! Which!vaccines!have!been!introduced!into!the!national!vaccination!programme/!
introduced!in!demonstration!projects!in!the!last!five!years?!What!information!was!
required!in!order!to!introduce!these!new!vaccines?!How!was!the!final!decision!
arrived!at?!What!factors!influenced!these!decisions?!
!
